Table 4.
Individual patient-level data meta-analysis: Factors associated with HCC, cirrhosis, mortality and HBsAg seroclerance among patients with and without fatty liver among IPTW cohort*
| Subgroups | Number of events | Hazard ratios (95% CI) | P-value |
|---|---|---|---|
| HCC | |||
| Non-fatty liver | 206 | 1 | |
| Fatty liver | 82 | 0.68 (0.52–0.88) | 0.004 |
| Cirrhosis | |||
| Non-fatty liver | 339 | 1 | |
| Fatty liver | 127 | 0.61 (0.49–0.75) | <0.0001 |
| Mortality | |||
| Non-fatty liver | 131 | 1 | |
| Fatty liver | 30 | 0.38 (0.25–0.57) | <0.0001 |
| HBsAg seroclerance | |||
| Non-fatty liver | 333 | 1 | |
| Fatty liver | 248 | 1.35 (1.14–1.60) | <0.0001 |
HCC, hepatocellular carcinoma; IPTW: Inverse Probability Treatment Weighting; ALT, alanine transaminases; HBV, hepatitis B virus.
*
Inverse Probability Treatment Weighting, matched for age, sex, baseline cirrhosis, diabetes mellitus, ALT, HBeAg, log HBV DNA, and antiviral treatment status.